Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Releases Earnings Results, Beats Expectations By $0.10 EPS

Key Points

• Bayer Aktiengesellschaft reported quarterly earnings of $0.35 EPS, exceeding analysts' expectations of $0.25 by $0.10.
• The company's revenue reached $12.42 billion, significantly higher than the consensus estimate of $10.79 billion.
• Despite the positive earnings report, analysts' ratings have varied, with some firms downgrading the stock while others have upgraded it to a strong-buy rating.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $0.35 EPS for the quarter, topping analysts' consensus estimates of $0.25 by $0.10, Zacks reports. Bayer Aktiengesellschaft had a positive return on equity of 15.48% and a negative net margin of 7.61%. The company had revenue of $12.42 billion for the quarter, compared to the consensus estimate of $10.79 billion.

Bayer Aktiengesellschaft Stock Up 2.1%

Shares of Bayer Aktiengesellschaft stock opened at $7.40 on Friday. The stock's fifty day moving average is $7.82 and its 200-day moving average is $6.72. The firm has a market capitalization of $29.08 billion, a PE ratio of -7.63 and a beta of 0.91. The company has a quick ratio of 0.79, a current ratio of 1.25 and a debt-to-equity ratio of 1.07. Bayer Aktiengesellschaft has a 12-month low of $4.79 and a 12-month high of $8.65.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BAYRY. Wall Street Zen downgraded Bayer Aktiengesellschaft from a "buy" rating to a "hold" rating in a research note on Saturday, July 26th. The Goldman Sachs Group raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Hsbc Global Res raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, June 11th. Finally, Kepler Capital Markets raised Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report on Wednesday, June 11th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy".

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.